Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 44Breast Neoplasms 30Lymphoma 29Sarcoma 27Hodgkin Disease 24Triple Negative Breast Neoplasms 20Burkitt Lymphoma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Neoplasms 15Lymphoma, Follicular 15Ovarian Neoplasms 14Lymphoma, B-Cell 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 9Endometrial Neoplasms 9Neuroblastoma 7Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Liposarcoma 7Leukemia 7Fallopian Tube Neoplasms 7Recurrence 6Multiple Myeloma 6Leiomyosarcoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Osteosarcoma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Inflammatory Breast Neoplasms 5

Interventions

pembrolizumab 6Injections 6senaparib 4toripalimab 3tislelizumab 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × Doxorubicin × 1 year × Clear all
NCT05661201 2026-03-06

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Georgetown University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡